Unrelated Medical Costs in Life-Years Gained: Should They be Included in Economic Evaluations of Healthcare Interventions?

Author： Rappange David R.

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.26, Iss.10, 2008-01, pp. : 815-830

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bivalirudin to replace heparin in coronary interventions?

Inpharma, Vol. 1, Iss. 1373, 2003-01 ,pp. : 13-14

Adis International

Access to resources Recommend Favorite

Including Indirect Medical Care Costs from Survivor Years of Life in Economic Evaluations

By Nyman John A. Jalal Hawre J.

PharmacoEconomics, Vol. 29, Iss. 3, 2011-03 ,pp. : 173-174

Adis International

Access to resources Recommend Favorite

Standardizing the Inclusion of Indirect Medical Costs in Economic Evaluations

By van Baal Pieter H.M. Wong Albert Slobbe Laurentius C.J.

PharmacoEconomics, Vol. 29, Iss. 3, 2011-03 ,pp. : 175-187

Adis International

Access to resources Recommend Favorite

Should healthcare spending be capped at a percentage of GDP?

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 563, 2008-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Is pharma to blame for soaring US healthcare costs?

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 396, 2003-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite